Mabtech and Sai Life Sciences announced a strategic collaboration that designates Sai’s Boston laboratory as a co-marketed U.S. execution and demonstration hub for the Mabtech EYRA platform, expanding access to advanced immunology assay services for biopharma and biotech companies. Under the agreement, the EYRA platform is installed at Sai’s Boston discovery site, enabling delivery of high-sensitivity multiplex cytokine and phenotyping workflows to support research in immuno-oncology, vaccines, inflammation, and cellular therapy. “We’re excited to see EYRA placed at Sai Life Sciences and integrated into their US discovery operations,” said Kimberlee Parent, Head of US Operations at Mabtech. “This installation enables Sai to offer EYRA’s powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. Together, Mabtech’s assay expertise and Sai’s strong discovery and translational capabilities create a compelling new service offering for researchers.”
Also Read: Snowflake Introduces Energy Solutions for AI Data Cloud to Lower-Carbon Future
EYRA combines intuitive software, automation readiness, and simultaneous detection of dozens of analytes with minimal hands-on time, addressing limitations of traditional assay systems. “For our discovery clients, the ability to generate reliable, decision-enabling data early is critical,” said Maneesh Pingle, Head of Discovery Services at Sai Life Sciences. “By establishing our Boston site as a US execution hub for EYRA-enabled immunology workflows, we are strengthening Sai’s capability to support complex programs in immunology and immuno-oncology.